SCHEMBL25317065

SCHEMBL25317065

Cn1cc(-c2ccc(O)cc2)nc1C1CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.41
MAPT P10636 2/20 0.41
USP7 Q93009 1/20 0.40
ESR2 Q92731 1/20 0.40
ALDH1A1 P00352 2/20 0.39
POLB P06746 2/20 0.39
HPGD P15428 2/20 0.39
HSD17B10 Q99714 1/20 0.39
RPS6KB1 P23443 6/20 0.39
KDM4E B2RXH2 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
GFER P55789 2/20 0.39
AKT1 P31749 4/20 0.38
PDE10A Q9Y233 1/20 0.37
AKT2 P31751 1/20 0.37
KCNH2 Q12809 1/20 0.37
AKT3 Q9Y243 1/20 0.37
HSD11B1 P28845 1/20 0.36
MAOB P27338 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2682489 0.84 NPC1 (0.43) MAPTALDH1A1POLBHPGDHSD17B10
SCHEMBL25317963 0.75 LPL (0.43) RPS6KB1AKT1
SCHEMBL22165867 0.74 PTGS1 (0.41) PTGS1MAPTUSP7ESR2ALDH1A1
SCHEMBL19529677 0.74 PTGS1 (0.61) PTGS1MAPTUSP7ESR2ALDH1A1
SCHEMBL21051588 0.74 PTGS1 (0.51) PTGS1MAPTUSP7ESR2ALDH1A1
SCHEMBL31351719 0.73 RPS6KB1 (0.37) RPS6KB1AKT1AKT2KCNH2AKT3
SCHEMBL25315329 0.73 DRD2 (0.43) RPS6KB1AKT1AKT2KCNH2AKT3
SCHEMBL407247 0.73 TDP1 (0.49) MAPTALDH1A1HPGDHSD17B10NPC1
SCHEMBL440139 0.73 TDP1 (0.49) MAPTALDH1A1HPGDHSD17B10NPC1
SCHEMBL22347198 0.73 ALDH1A1 (0.44) MAPTALDH1A1POLBHPGDRPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747244-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE Redx Pharma Limited (GB) 2026-05-27 EP disclosed
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2025-04-17 US disclosed
WO-2025017306-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2025-01-23 WO disclosed
WO-2025017305-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LIMITED (GB) 2025-01-23 WO disclosed
EP-4466071-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) Redx Pharma Limited (GB) 2024-11-27 EP disclosed
CN-118632845-A Modulators of Rho-associated protein kinase (ROCK) 莱德克斯制药有限公司 2024-09-10 CN disclosed
WO-2023139379-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) REDX PHARMA PLC (GB) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK1, ROCK2, RHOA PTGS1 434/4885MAPT 686/4885USP7 3635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.